These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 198969)

  • 41. Partial inhibition of vesicular stomatitis virus by the interferon-induced human 9-27 protein.
    Alber D; Staeheli P
    J Interferon Cytokine Res; 1996 May; 16(5):375-80. PubMed ID: 8727077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantification of the antiviral effect of interferon by immunoassay of vesicular stomatitis virus proteins.
    Wallach D
    J Gen Virol; 1983 Oct; 64 (Pt 10)():2221-7. PubMed ID: 6194250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rat interferons. VI. Heterologous interferon in the treatment of viral infections.
    Lobodzińska M; Albin M
    Arch Immunol Ther Exp (Warsz); 1979; 27(1-2):247-52. PubMed ID: 220932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transforming growth factor-beta inhibits the antiviral action of interferons in human embryonic fibroblasts.
    Zielińska-Jenczylik J; Inglot AD; Inglot O; Popik W
    J Interferon Res; 1991 Apr; 11(2):87-9. PubMed ID: 1714487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Method of increasing the activity of a preparation of human cadaver leukocyte interferon].
    Parfenov VV; Zubanova NA; Mekhedov LN; Pokidysheva LN; Kuznetsov VP
    Vopr Virusol; 1980; (3):294-7. PubMed ID: 6159731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies of L cells persistently infected with VSV: factors involved in the regulation of persistent infection.
    Nishiyama Y
    J Gen Virol; 1977 May; 35(2):265-79. PubMed ID: 195007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of exogenous interferon on virus-specific immune cytolysis].
    Ovsiannikova NV; Karmysheva VIa
    Vopr Virusol; 1980; (1):72-6. PubMed ID: 6158178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endogenous interferon (IFN) in patients with acute hepatitis B.
    Boron-Kaczmarska A; Zachoval R; Zachoval V; Deinhardt F
    Acta Med Hung; 1990; 47(1-2):77-80. PubMed ID: 1704122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Differences in the properties of the interferons produced by the leukocytes of healthy persons and of cancer and leukemia patients].
    Pokidysheva LN; Marchenko VI; Zubanova NA; Moĭsiadi SA; Fedorova IuB
    Vopr Virusol; 1979; (5):532-5. PubMed ID: 506207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential sensitivity of Rauscher murine leukaemia virus (MuLV-R) to interferons in two interferon-responsive cell lines.
    Allen PT; Schellekens H; Van Griensven LJ; Billiau A
    J Gen Virol; 1976 Jun; 31(3):429-35. PubMed ID: 58965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Fractional composition of the RNA of mouse Krebs-II ascitic cell tumor and rat ovarian carcinoma].
    Chichinadze MV; Kalinovskiĭ VP; Goriukhina TA
    Vopr Onkol; 1976; 22(7):61-4. PubMed ID: 1033638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mx gene control of interferon action: different kinetics of the antiviral state against influenza virus and vesicular stomatitis virus.
    Arnheiter H; Haller O
    J Virol; 1983 Sep; 47(3):626-30. PubMed ID: 6312087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon and cell division. I. Inhibition of the multiplication of mouse leukemia L 1210 cells in vitro by interferon preparations.
    Gresser I; Brouty-Boyé D; Thomas MT; Macieira-Coelho A
    Proc Natl Acad Sci U S A; 1970 Aug; 66(4):1052-8. PubMed ID: 4319881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of gamma interferon preparations on in vitro phagocytosis and degradation of Escherichia coli by mouse peritoneal macrophages.
    Degré M; Sonnenfeld G; Rollag H; Mørland B
    J Interferon Res; 1981; 1(4):505-12. PubMed ID: 6180084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Establishment of the interferon-mediated antiviral state: role of fatty acid cyclooxygenase.
    Pottathil R; Chandrabose KA; Cuatrecasas P; Lang DJ
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5437-40. PubMed ID: 6159647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Relationship between manifestation of hyporeactivity (tolerance) in interferon production and the presence of a viral interferon inductor in the cells of the tolerant animal].
    Marchenko VI; Zubanova NA; Diuĭsalieva RG; Voronina FV; Delimbetova GA
    Vopr Virusol; 1977; (2):206-15. PubMed ID: 898897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chronic viral infection in transplantable cultures of human leukemia (J-96) and mouse fibroblast (L) cells, produced by inoculation of the cultures with Coxsackie B5 and vesicular stomatitis viruses in the presence of antisera to the infected cells].
    Sovetova GP; Marchenko VI; Amchenkova AM; Balandin IG; Lushinkov AA
    Vopr Virusol; 1971; 16(1):10-6. PubMed ID: 4327850
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of interferon preparations on the uptake of non-opsonized Escherichia coli by mouse peritoneal macrophages.
    Rollag H; Degré M
    Acta Pathol Microbiol Scand B; 1981 Jun; 89(3):153-9. PubMed ID: 6171991
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The capacity of interferon-insensitive cells to prevent the development of an antiviral condition].
    Narovlianskiĭ AN; Amchenkova AM; Pokidysheva LN; Khesin IaE
    Vopr Virusol; 1988; 33(3):351-4. PubMed ID: 2459852
    [No Abstract]   [Full Text] [Related]  

  • 60. Induction of an inhibitor of interferon action in a mouse lymphokine preparation.
    Fleischmann WR; Georgiades JA; Osborne LC; Dianzani F; Johnson HM
    Infect Immun; 1979 Dec; 26(3):949-55. PubMed ID: 231012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.